Skip to main content
Erschienen in: Tumor Biology 3/2013

01.06.2013 | Research Article

Apoptin induces apoptosis in nude mice allograft model of human bladder cancer by altering multiple bladder tumor-associated gene expression profiles

verfasst von: Chunhui Wang, Wenju Wang, Jiansong Wang, Hui Zhan, Lihong Jiang, Ruping Yan, Zongliu Hou, Huirong Zhu, Lirui Yu, Yunqiang Shi, Mingxia Ding, Changxing Ke

Erschienen in: Tumor Biology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Bladder cancer (BC) is one of the most common human malignancies that account for major death in the world. Apoptin that is derived from chicken anemia virus (CAV) has displayed tumor-specific cytotoxic activity in a variety of human carcinomas. However, the magical function of apoptin in bladder carcinoma cell lines has not been identified yet. In our study, we delivered apoptin into bladder-originating T24, EJ, and HCV29 cell lines by adenovirus system. The selective cytotoxic effect of apoptin was determined by cell viability assay, active caspase-3 measurement, and annexin V/PI double staining. Importantly, we have examined the differential expression patterns of tumor-associated genes including Ki67, C-erbB-2, Rb, and nm23 by flow cytometry and western blot in vitro. In an animal study, apoptin was infused into animal models by AAV system, and immunohistochemistry and quantitative real-time PCR (qRT-PCR) were employed to validate results in vivo. The results indicated that apoptin could selectively induce apoptosis in bladder tumorigenic cells coupled with tumor-specific nucleus accumulation in vitro. Interestingly, apoptin could downregulate expression levels of Ki67 and C-erbB-2 and upregulate the expression of Rb both in vitro and in vivo. Moreover, the animal models treated with AAV-apoptin have shown smaller tumor volumes and displayed better prognosis than controls. In conclusion, apoptin could selectively induce apoptosis in bladder tumor cells through altering expression profiles of tumor-associated genes.
Literatur
1.
Zurück zum Zitat Burger M, Catto J W F, Dalbagni G, Grossman H B, Herr H, Karakiewicz P, Kassouf W, Kiemeney L A, La Vecchia CShariat S. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2012; Burger M, Catto J W F, Dalbagni G, Grossman H B, Herr H, Karakiewicz P, Kassouf W, Kiemeney L A, La Vecchia CShariat S. Epidemiology and risk factors of urothelial bladder cancer. European urology. 2012;
2.
Zurück zum Zitat Philips BJ, Coyle CH, Morrisroe SN, Chancellor M, BYoshimura N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009;30:207–15.PubMedCrossRef Philips BJ, Coyle CH, Morrisroe SN, Chancellor M, BYoshimura N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009;30:207–15.PubMedCrossRef
3.
Zurück zum Zitat Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol. 2000;18:280–8.PubMed Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol. 2000;18:280–8.PubMed
4.
Zurück zum Zitat Pan JG, Zhou X, Zeng G, WHan RF. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biology. 2011;32:301–10.PubMedCrossRef Pan JG, Zhou X, Zeng G, WHan RF. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biology. 2011;32:301–10.PubMedCrossRef
5.
Zurück zum Zitat Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61:299–305.PubMedCrossRef Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61:299–305.PubMedCrossRef
6.
Zurück zum Zitat Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa KOya M. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Human Gene Therapy. 2011;22:1423–32.PubMedCrossRef Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, Nakagawa KOya M. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Human Gene Therapy. 2011;22:1423–32.PubMedCrossRef
7.
Zurück zum Zitat Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann FSchulze-Osthoff K. Apoptin, a tumor-selective killer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2009;1793:1335–42.CrossRef Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann FSchulze-Osthoff K. Apoptin, a tumor-selective killer. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2009;1793:1335–42.CrossRef
8.
Zurück zum Zitat Rohn JNoteborn M. The viral death effector apoptin reveals tumor-specific processes. Apoptosis. 2004;9:315–22.CrossRef Rohn JNoteborn M. The viral death effector apoptin reveals tumor-specific processes. Apoptosis. 2004;9:315–22.CrossRef
9.
Zurück zum Zitat Zhou S, Zhang M, Zhang J, Shen H, Tangsakar EWang J. Mechanisms of apoptin-induced cell death. Medical Oncology. 2011;1–7 Zhou S, Zhang M, Zhang J, Shen H, Tangsakar EWang J. Mechanisms of apoptin-induced cell death. Medical Oncology. 2011;1–7
10.
Zurück zum Zitat Pietersen ANoteborn M H M. Apoptin®. Cancer Gene Therapy. 2002;153–161 Pietersen ANoteborn M H M. Apoptin®. Cancer Gene Therapy. 2002;153–161
11.
Zurück zum Zitat Poon I, Oro C, Dias M, Zhang J, PJans D. A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J Virol. 2005;79:1339–41.PubMedCrossRef Poon I, Oro C, Dias M, Zhang J, PJans D. A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J Virol. 2005;79:1339–41.PubMedCrossRef
12.
Zurück zum Zitat Danen-Van Oorschot A, Fischer D, Grimbergen JM, Klein B, Zhuang SM, Falkenburg J, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci. 1997;94:5843–7.PubMedCrossRef Danen-Van Oorschot A, Fischer D, Grimbergen JM, Klein B, Zhuang SM, Falkenburg J, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci. 1997;94:5843–7.PubMedCrossRef
13.
Zurück zum Zitat Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb A, JNoteborn MHM. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. 1995;55:486–9.PubMed Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb A, JNoteborn MHM. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. 1995;55:486–9.PubMed
14.
Zurück zum Zitat Danen-van Oorschot A, van Der Eb ANoteborn M. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol. 2000;74:7072–8.PubMedCrossRef Danen-van Oorschot A, van Der Eb ANoteborn M. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol. 2000;74:7072–8.PubMedCrossRef
15.
Zurück zum Zitat Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH. BCL-2 stimulates apoptin-induced apoptosis. Adv Exp Med Biol. 1999;457:245–9.PubMedCrossRef Danen-Van Oorschot AA, van der Eb AJ, Noteborn MH. BCL-2 stimulates apoptin-induced apoptosis. Adv Exp Med Biol. 1999;457:245–9.PubMedCrossRef
16.
Zurück zum Zitat Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH. The effect of Bcl-2 on Apoptin in ‘normal’ vs. transformed human cells. Leukemia. 1999;13(1):S75–7.PubMed Danen-Van Oorschot AA, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MH. The effect of Bcl-2 on Apoptin in ‘normal’ vs. transformed human cells. Leukemia. 1999;13(1):S75–7.PubMed
17.
Zurück zum Zitat Takahashi R, Hashimoto T, Xu HJ, Hu SX, Matsui T, Miki T, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci. 1991;88:5257.PubMedCrossRef Takahashi R, Hashimoto T, Xu HJ, Hu SX, Matsui T, Miki T, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci. 1991;88:5257.PubMedCrossRef
18.
Zurück zum Zitat Enache M, SIMIONESCU CLASCU LC. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma. Romanian journal of morphology and embryology. Revue Roumaine de Morphologie et Embryologie. 2012;53:521.PubMed Enache M, SIMIONESCU CLASCU LC. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma. Romanian journal of morphology and embryology. Revue Roumaine de Morphologie et Embryologie. 2012;53:521.PubMed
19.
Zurück zum Zitat Fleischmann A, Rotzer D, Seiler R, Studer U, EThalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7.PubMedCrossRef Fleischmann A, Rotzer D, Seiler R, Studer U, EThalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350–7.PubMedCrossRef
20.
Zurück zum Zitat Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res. 2000;20:5023–8.PubMed Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res. 2000;20:5023–8.PubMed
21.
Zurück zum Zitat Desilet N, Campbell TN, Choy FY. p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol. 2010;12:143–6.PubMed Desilet N, Campbell TN, Choy FY. p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol. 2010;12:143–6.PubMed
22.
Zurück zum Zitat Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 2006;66:9356–61.PubMedCrossRef Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, et al. Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res. 2006;66:9356–61.PubMedCrossRef
24.
Zurück zum Zitat Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, González GApolinario R. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol. 1998;49:163–7.PubMedCrossRef Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, González GApolinario R. The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol. 1998;49:163–7.PubMedCrossRef
25.
Zurück zum Zitat Teodoro JG, Heilman DW, Parker A, EGreen MR. The viral protein apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004;18:1952–7.PubMedCrossRef Teodoro JG, Heilman DW, Parker A, EGreen MR. The viral protein apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004;18:1952–7.PubMedCrossRef
26.
Zurück zum Zitat Grossman HB, Liebert M, Antelo M, Dinney C, Hu SX, Palmer J, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829–34.PubMed Grossman HB, Liebert M, Antelo M, Dinney C, Hu SX, Palmer J, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4:829–34.PubMed
27.
Zurück zum Zitat Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6:e27616.PubMedCrossRef Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6:e27616.PubMedCrossRef
28.
Zurück zum Zitat Wright C, Mellon K, Neal D, Johnston P, Corbett I, Horne C. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990;62:764.PubMedCrossRef Wright C, Mellon K, Neal D, Johnston P, Corbett I, Horne C. Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer. 1990;62:764.PubMedCrossRef
29.
Zurück zum Zitat Marín ÁP, Arranz EE, Sánchez AR, Auñón PZ, Barón MG. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol. 2010;136:1915–20.PubMedCrossRef Marín ÁP, Arranz EE, Sánchez AR, Auñón PZ, Barón MG. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol. 2010;136:1915–20.PubMedCrossRef
30.
Zurück zum Zitat Chow NH, Liu HS, Chan SH. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res. 2000;6:3595–9.PubMed Chow NH, Liu HS, Chan SH. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res. 2000;6:3595–9.PubMed
Metadaten
Titel
Apoptin induces apoptosis in nude mice allograft model of human bladder cancer by altering multiple bladder tumor-associated gene expression profiles
verfasst von
Chunhui Wang
Wenju Wang
Jiansong Wang
Hui Zhan
Lihong Jiang
Ruping Yan
Zongliu Hou
Huirong Zhu
Lirui Yu
Yunqiang Shi
Mingxia Ding
Changxing Ke
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0700-8

Weitere Artikel der Ausgabe 3/2013

Tumor Biology 3/2013 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.